Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
American Journal of Cardiovascular Drugs
Published in: American Journal of Cardiovascular Drugs 1/2006

01-01-2006 | Review Article

Vasopressin During Cardiopulmonary Resuscitation and Different Shock States

A Review of the Literature

Authors: Dr Anette C. Krismer, Martin W. Dünser, Karl H. Lindner, Karl H. Stadlbauer, Viktoria D. Mayr, Hannes G. Lienhart, Richard H. Arntz, Volker Wenzel

Published in: American Journal of Cardiovascular Drugs | Issue 1/2006

Login to get access

Abstract

Vasopressin administration may be a promising therapy in the management of various shock states. In laboratory models of cardiac arrest, vasopressin improved vital organ blood flow, cerebral oxygen delivery, the rate of return of spontaneous circulation, and neurological recovery compared with epinephrine (adrenaline). In a study of 1219 adult patients with cardiac arrest, the effects of vasopressin were similar to those of epinephrine in the management of ventricular fibrillation and pulseless electrical activity; however, vasopressin was superior to epinephrine in patients with asystole. Furthermore, vasopressin followed by epinephrine resulted in significantly higher rates of survival to hospital admission and hospital discharge. The current cardiopulmonary resuscitation guidelines recommend intravenous vasopressin 40IU or epinephrine 1mg in adult patients refractory to electrical countershock. Several investigations have demonstrated that vasopressin can successfully stabilize hemodynamic variables in advanced vasodilatory shock. Use of vasopressin in vasodilatory shock should be guided by strict hemodynamic indications, such as hypotension despite norepinephrine (noradrenaline) dosages >0.5βlg/kg/min. Vasopressin must never be used as the sole vasopressor agent. In our institutional routine, a fixed vasopressin dosage of 0.067 IU/min (i.e. 100 IU/50mL at 2 mL/h) is administered and mean arterial pressure is regulated by adjusting norepinephrine infusion. When norepinephrine dosages decrease to 0.2βg/kg/min, vasopressin is withdrawn in small steps according to the response in mean arterial pressure. Vasopressin also improved short-and long-term survival in various porcine models of uncontrolled hemorrhagic shock. In the clinical setting, we observed positive effects of vasopressin in some patients with life-threatening hemorrhagic shock, which had no longer responded to adrenergic catecholamines and fluid resuscitation. Clinical employment of vasopressin during hemorrhagic shock is experimental at this point in time.
Literature
1.
Sklar AH, Schrier RW. Central nervous system mediators of vasopressin release. Physiol Rev 1983; 63: 1243–80.PubMed
2.
Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med 2004; 30: 1276–91.PubMed
3.
Schmittinger CA, Wenzel V, Herff H, et al. Drug therapy during CPR [in German]. Anasthesiol Intensivmed Notfallmed Schmerzther 2003; 38: 651–72.PubMedCrossRef
4.
Thrasher TN, Keil LC. Systolic pressure predicts plasma vasopressin responses to hemorrhage and vena caval constriction in dogs. Am J Physiol Regul Integr Comp Physiol 2000; 279: R1035–1042.
5.
Berl T, Robertson GL. Pathophyisology of water metabolism. In: Brenner BM. editor. Brenner & Rector’s the kidney. Philadelphia (PA): Saunders, 2000: 866–924.
6.
Callahan MF, Ludwig M, Tsai KP, et al. Baroreceptor input regulates osmotic control of central vasopressin secretion. Neuroendocrinology 1997; 65: 238–45.PubMedCrossRef
7.
Kasting NW, Mazurek MF, Martin JB. Endotoxin increases vasopressin release independently of known physiological stimuli. Am J Physiol 1985; 248: E420–424.
8.
Wilson MF, Brackett DJ, Tompkins P, et al. Elevated plasma vasopressin concentrations during endotoxin and E. coli shock. Adv Shock Res 1981; 6: 15–26.PubMed
9.
Chikanza IC, Petrou P, Chrousos G. Perturbations of arginine vasopressin secretion during inflammatory stress: pathophysiologic implications. Ann N Y Acad Sci 2000; 917: 825–34.PubMedCrossRef
10.
Mastorakos G, Weber JS, Magiakou MA, et al. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol Metab 1994; 79: 934–9.PubMedCrossRef
11.
Zelazowski P, Patchev VK, Zelazowska EB, et al. Release of hypothalamic corticotropin-releasing hormone and arginine-vasopressin by interleukin 1 beta and alpha MSH: studies in rats with different susceptibility to inflammatory disease. Brain Res 1993; 631: 22–6PubMedCrossRef
12.
Muders F, Eisner D, Jandeleit K, et al. Chronic ACE inhibition by quinapril modulates central vasopressinergic system. Cardiovasc Res 1997; 34: 575–81.PubMedCrossRef
13.
Calogero AE, Fornito MC, Aliffi A, et al. Role of peripherally infused angiotensin II on the human hypothalamic-pituitary-adrenal axis. Clin Endocrinol (Oxf) 1991; 34: 183–6.CrossRef
14.
Reaux A, Fournie-Zaluski MC, Llorens-Cortes C. Angiotensin III: a central regulator of vasopressin release and blood pressure. Trends Endocrinol Metab 2001; 12: 157–62.PubMedCrossRef
15.
Yamamoto T, Kimura T, Ota K, et al. Central effects of endothelin-1 on vasopressin and atrial natriuretic peptide release and cardiovascular and renal function in conscious rats. J Cardiovasc Pharmacol 1991; 17 Suppl. 7: S316–318.
16.
Standaert DG, Cechetto DF, Needleman P, et al. Inhibition of the firing of vasopressin neurons by atriopeptin. Nature 1987; 329: 151–3.PubMedCrossRef
17.
Obana K, Naruse M, Inagami T, et al. Atrial natriuretic factor inhibits vasopressin secretion from rat posterior pituitary. Biochem Biophys Res Commun 1985; 132: 1088–94.PubMedCrossRef
18.
Sharshar T, Blanchard A, Paillard M, et al. Circulating vasopressin levels in septic shock. Crit Care Med 2003; 31: 1752–8.PubMedCrossRef
19.
20.
Reid IA, Schwartz J. Role of vasopressin in the control of blood pressure. In: Martini L, Ganong WF, editors. Frontiers in neuroendocrinology. New York: Raven Press, 1976: 177–97.
21.
Fox AW, May RE, Mitch WE. Comparison of peptide and nonpeptide receptormediated responses in rat tail artery. J Cardiovasc Pharmacol 1992; 20: 282–9.PubMedCrossRef
22.
Garcia-Villalon AL, Garcia JL, Fernandez N, et al. Regional differences in the arterial response to vasopressin: role of endothelial nitric oxide. Br J Pharmacol 1996; 118: 1848–54.PubMedCrossRef
23.
Moursi MM, van Wylen DG, D’Alecy LG. Regional blood flow changes in response to mildly pressor doses of triglycyl desamino lysine and arginine vasopressin in the conscious dog. J Pharmacol Exp Ther 1985; 232: 360–8.PubMed
24.
Voelckel WG, Lindner KH, Wenzel V, et al. Effects of vasopressin and epinephrine on splanchnic blood flow and renal function during and after cardiopulmonary resuscitation in pigs. Crit Care Med 2000; 28: 1083–8.PubMedCrossRef
25.
Martinez MC, Vila JM, Aldasoro M, et al. Relaxation of human isolated mesenteric arteries by vasopressin and desmopressin. Br J Pharmacol 1994; 113: 419–24.PubMedCrossRef
26.
Wallace AW, Tunin CM, Shoukas AA. Effects of vasopressin on pulmonary and systemic vascular mechanics. Am J Physiol 1989; 257: H1228–34.PubMed
27.
Okamura T, Ayajiki K, Fujioka H, et al. Mechanisms underlying arginine vasopressin-induced relaxation in monkey isolated coronary arteries. J Hypertens 1999; 17: 673–8.PubMedCrossRef
28.
Suzuki Y, Satoh S, Oyama H, et al. Vasopressin mediated vasodilation of cerebral arteries. J Auton Nerv Syst 1994; 49 Suppl.: S129–132.
29.
Russ RD, Walker BR. Role of nitric oxide in vasopressinergic pulmonary vasodilatation. Am J Physiol 1992; 262: H743–747.
30.
Xu YJ, Gopalakrishnan V. Vasopressin increases cytosolic free (Ca2+) in the neonatal rat cardiomyocyte: evidence for V1 subtype receptors. Circ Res 1991; 69: 239–45.PubMedCrossRef
31.
Fujisawa S, Iijima T. On the inotropic actions of arginine vasopressin in ventricular muscle of the guinea pig heart. Jpn J Pharmacol 1999; 81: 309–12.PubMedCrossRef
32.
Wuttke T. Endokrinology. In: Schmidt RF, Thews G, editors. Human physiology. Berlin: Springer, 1993: 390–420.
33.
Landry DW, Levin HR, Gallant EM, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997; 25: 1279–82.PubMedCrossRef
34.
Tsuneyoshi I, Yamada H, Kakihana Y, et al. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001; 29: 487–93.PubMedCrossRef
35.
Holmes CL, Walley KR, Chittock DR, et al. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 2001; 27: 1416–21.PubMedCrossRef
36.
Mannucci PM, Canciani MT, Rota L, et al. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand’s disease. Br J Haematol 1981; 47: 283–93.PubMedCrossRef
37.
Mannucci PM, Remuzzi G, Pusineri F, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983; 308: 8–12.PubMedCrossRef
38.
Salzman EW, Weinstein MJ, Weintraub RM, et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery: a double-blind randomized trial. N Engl J Med 1986; 314: 1402–6.PubMedCrossRef
39.
Diinser MW, Mayr AJ, Ulmer H, et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg 2001; 93: 7–13.CrossRef
40.
Diinser MW, Fries DR, Schobersberger W, et al. Does arginine vasopressin influence the coagulation system in advanced vasodilatory shock with severe multiorgan dysfunction syndrome? Anesth Analg 2004; 99: 201–6.CrossRef
41.
Bilezikjian LM, Vale WW. Regulation of ACTH secretion from corticotrophs: the interaction of vasopressin and CRF. Ann N Y Acad Sci 1987; 512: 85–96.PubMedCrossRef
42.
Kornberger E, Prengel AW, Krismer A, et al. Vasopressin-mediated adrenocorticotropin release increases plasma Cortisol concentrations during cardiopulmonary resuscitation. Crit Care Med 2000; 28: 3517–21.PubMedCrossRef
43.
DÜnser MW, Hasibeder WR, Wenzel V, et al. Endocrinologic response to vasopressin infusion in advanced vasodilatory shock. Crit Care Med 2004; 32: 1266–71.PubMedCrossRef
44.
Lee B, Yang C, Chen TH, et al. Effect of AVP and oxytocin on insulin release: involvement of V1b receptors. Am J Physiol 1995; 269: E1095–100.PubMed
45.
Lindner KH, Prengel AW, Pfenninger EG, et al. Vasopressin improves vital organ blood flow during closed-chest cardiopulmonary resuscitation in pigs. Circulation 1995; 91: 215–21.PubMedCrossRef
46.
Prengel AW, Lindner KH, Keller A. Cerebral oxygenation during cardiopulmonary resuscitation with epinephrine and vasopressin in pigs. Stroke 1996; 27: 1241–8.PubMedCrossRef
47.
Wenzel V, Lindner KH, Prengel AW, et al. Vasopressin improves vital organ blood flow after prolonged cardiac arrest with postcountershock pulseless electrical activity in pigs. Crit Care Med 1999; 27: 486–92.PubMedCrossRef
48.
Wenzel V, Lindner KH, Prengel AW, et al. Endobronchial vasopressin improves survival during cardiopulmonary resuscitation in pigs. Anesthesiology 1997; 86: 1375–81.PubMedCrossRef
49.
Wenzel V, Prengel AW, Lindner KH. A strategy to improve endobronchial drug administration. Anesth Analg 2000; 91: 255–6.PubMed
50.
Wenzel V, Lindner KH, Augenstein S, et al. Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. Crit Care Med 1999; 27: 1565–9.PubMedCrossRef
51.
Wenzel V, Lindner KH, Krismer AC, et al. Repeated administration of vasopressin but not epinephrine maintains coronary perfusion pressure after early and late administration during prolonged cardiopulmonary resuscitation in pigs. Circulation 1999; 99: 1379–84.PubMedCrossRef
52.
Prengel AW, Lindner KH, Keller A, et al. Cardiovascular function during the postresuscitation phase after cardiac arrest in pigs: a comparison of epinephrine versus vasopressin. Crit Care Med 1996; 24: 2014–9.PubMedCrossRef
53.
Lindner KH, Brinkmann A, Pfenninger EG, et al. Effect of vasopressin on hemodynamic variables, organ blood flow, and acid-base status in a pig model of cardiopulmonary resuscitation. Anesth Analg 1993; 77: 427–35.PubMedCrossRef
54.
Prengel AW, Lindner KH, Wenzel V, et al. Splanchnic and renal blood flow after cardiopulmonary resuscitation with epinephrine and vasopressin in pigs. Resuscitation 1998; 38: 19–24.PubMedCrossRef
55.
Wenzel V, Lindner KH, Krismer AC, et al. Survival with full neurologic recovery and no cerebral pathology after prolonged cardiopulmonary resuscitation with vasopressin in pigs. J Am Coll Cardiol 2000; 35: 527–33.PubMedCrossRef
56.
Lindner KH, Prengel AW, Brinkmann A, et al. Vasopressin administration in refractory cardiac arrest. Ann Intern Med 1996; 124: 1061–4.PubMed
57.
Lindner KH, Dirks B, Strohmenger HU, et al. A randomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet 1997; 349: 535–7.PubMedCrossRef
58.
Li PF, Chen TT, Zhang JM. Clinical study on administration of vasopressin during closed-chest cardiopulmonary resuscitation. Chin Crit Care Med 1999; 11: 28–31.
59.
Stiell IG, Hebert PC, Wells GA, et al. Vasopressin versus epinephrine for inhospital cardiac arrest: a randomised controlled trial. Lancet 2001; 358: 105–9.PubMedCrossRef
60.
Morris DC, Dereczyk BE, Grzybowski M, et al. Vasopressin can increase coronary perfusion pressure during human cardiopulmonary resuscitation. Acad Emerg Med 1997; 4: 878–83.PubMedCrossRef
61.
Wenzel V, Krismer AC, Arntz HR, et al. A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med 2004; 350: 105–13.PubMedCrossRef
62.
Babar SI, Berg RA, Hilwig RW, et al. Vasopressin versus epinephrine during cardiopulmonary resuscitation: a randomized swine outcome study. Resuscitation 1999; 41: 185–92.PubMedCrossRef
63.
Paradis NA, Wenzel V, Southall J. Pressor drugs in the treatment of cardiac arrest. Cardiol Clin 2002; 20: 61–78.PubMedCrossRef
64.
Paradis NA, Martin GB, Rivers EP, et al. Coronary perfusion pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation. JAMA 1990; 263: 1106–13.PubMedCrossRef
65.
Mayr VD, Wenzel V, Voelckel WG, et al. Developing a vasopressor combination in a pig model of adult asphyxiai cardiac arrest. Circulation 2001; 104: 1651–6.PubMedCrossRef
66.
Guyette FX, Guimond GE, Hostler D, et al. Vasopressin administered with epinephrine is associated with a return of a pulse in out-of-hospital cardiac arrest. Resuscitation 2004; 63: 277–82.PubMedCrossRef
67.
Grmec S, Kamenik B, Mally S. Vasopressin in refractory out-of-hospital ventricular fibrillation: preliminary results [abstract]. Crit Care Med 2002; 6: P162.
68.
Hypothermia After Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002; 346: 549–56.CrossRef
69.
70.
Aung K, Htay T. Vasopressin for cardiac arrest: a systematic review and metaanalysis. Arch Intern Med 2005; 165: 17–24.PubMedCrossRef
71.
Mayr VD, Wenzel V, Muller T, et al. Effects of vasopressin on left anterior descending coronary artery blood flow during extremely low cardiac output. Resuscitation 2004; 62: 229–35.PubMedCrossRef
72.
Wenzel V, Kern KB, Hilwig RW, et al. Effects of intravenous arginine vasopressin on epicardial coronary artery cross sectional area in a swine resuscitation model. Resuscitation 2005; 64: 219–26.PubMedCrossRef
73.
Wenzel V, Lindner KH. Employing vasopressin during cardiopulmonary resuscitation and vasodilatory shock as a lifesaving vasopressor. Cardiovasc Res 2001; 51: 529–41.PubMedCrossRef
74.
75.
Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004; 30(4): 536–55.PubMedCrossRef
76.
Parrillo JE. Management of septic shock: present and future. Ann Intern Med 1991; 115: 491–3.PubMed
77.
Schwartz J, Reid IA. Effect of vasopressin blockade on blood pressure regulation during hemorrhage in conscious dogs. Endocrinology 1981; 109: 1778–80.PubMedCrossRef
78.
Baker CH, Sutton ET, Zhou Z, et al. Microvascular vasopressin effects during endotoxin shock in the rat. Circ Shock 1990; 30: 81–95.PubMed
79.
Morales D, Madigan J, Cullinane S, et al. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Circulation 1999; 100: 226–9.PubMedCrossRef
80.
Errington ML, Rocha e Silva Jr M. Vasopressin clearance and secretion during haemorrhage in normal dogs and in dogs with experimental diabetes insipidus. J Physiol 1972; 227: 395–418.PubMed
81.
Morales DL, Gregg D, Helman DN, et al. Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. Ann Thorac Surg 2000; 69: 102–6.PubMedCrossRef
82.
Argenziano M, Chen JM, Choudhri AF, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998; 116: 973–80.PubMedCrossRef
83.
Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95: 1122–5.PubMedCrossRef
84.
Goldsmith SR. Vasopressin deficiency and vasodilation of septic shock. Circulation 1998; 97: 292–3.PubMedCrossRef
85.
Cooke CR, Wall BM, Jones GV, et al. Reversible vasopressin deficiency in severe hypernatremia. Am J Kidney Dis 1993; 22: 44–52.PubMed
86.
Argenziano M, Chen JM, Cullinane S, et al. Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. J Heart Lung Transplant 1999; 18: 814–7.PubMedCrossRef
87.
Argenziano M, Choudhri AF, Oz MC, et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997; 96: 11286–90.
88.
Cowley Jr AW, Quillen Jr EQ, Skelton MM. Role of vasopressin in cardiovascular regulation. Fed Proc 1983; 42: 3170–6.PubMed
89.
Annane D, Trabold F, Sharshar T, et al. Inappropriate sympathetic activation at onset of septic shock: a spectral analysis approach. Am J Respir Crit Care Med 1999; 160: 458–65.PubMed
90.
Undesser KP, Hasser EM, Haywood JR, et al. Interactions of vasopressin with the area postrema in arterial baroreflex function in conscious rabbits. Circ Res 1985; 56: 410–7.PubMedCrossRef
91.
Hasser EM, Undesser KP, Bishop VS. Interaction of vasopressin with area postrema during volume expansion. Am J Physiol 1987; 253: R605–610.
92.
Salzman AL, Vromen A, Denenberg A, et al. K(ATP)-channel inhibition improves hemodynamics and cellular energetics in hemorrhagic shock. Am J Physiol 1997; 272: H688–694.
93.
Nambi P, Whitman M, Gessner G, et al. Vasopressin-mediated inhibition of atrial natriuretic factor-stimulated cGMP accumulation in an established smooth muscle cell line. Proc Natl Acad Sci USA 1986; 83: 8492–5.PubMedCrossRef
94.
Nambi P, Whitman M, Aiyar N, et al. Inhibition of formation of cyclic AMP and cyclic GMP by vasopressin in smooth-muscle cells is insensitive to pertussis toxin. Biochem J 1988; 254: 449–53.PubMed
95.
Hamu Y, Kanmura Y, Tsuneyoshi I, et al. The effects of vasopressin on endotoxininduced attenuation of contractile responses in human gastroepiploic arteries in vitro. Anesth Analg 1999; 88: 542–8.PubMed
96.
Hollenberg SM, Piotrowski MJ, Parrillo JE. Nitric oxide synthase inhibition reverses arteriolar hyporesponsiveness to endothelin-1 in septic rats. Am J Physiol 1997; 272: R969–74.PubMed
97.
Schaller MD, Waeber B, Nussberger J, et al. Angiotensin II, vasopressin, and sympathetic activity in conscious rats with endotoxemia. Am J Physiol 1985; 249: H1086–92.PubMed
98.
Hollenberg SM, Tangora JJ, Piotrowski MJ, et al. Impaired microvascular vasoconstrictive responses to vasopressin in septic rats. Crit Care Med 1997; 25: 869–73.PubMedCrossRef
99.
Roth BL, Spitzer JA. Altered hepatic vasopressin and alpha 1-adrenergic receptors after chronic endotoxin infusion. Am J Physiol 1987; 252: E699–702.
100.
Rodriguez de Turco EB, Spitzer JA. Impairments in vasopressin-stimulated inositol lipid metabolism in hepatocytes of septic rats. Circ Shock 1988; 25: 299–307.PubMed
101.
Spitzer JA, Turco ER, Deaciuc IV, et al. Perturbation of transmembrane signaling mechanisms in acute and chronic endotoxemia. Prog Clin Biol Res 1987; 236A: 401–18.PubMed
102.
Malay MB, Ashton Jr RC, Landry DW, et al. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999; 47: 699–703.PubMedCrossRef
103.
Eichinger MR, Walker BR. Enhanced pulmonary arterial dilation to arginine vasopressin in chronically hypoxic rats. Am J Physiol 1994; 267: H2413–9.PubMed
104.
Filep JG, Földes-Filep É, Rousseau A, et al. Vascular responses to endothelin-1 following inhibition of nitric oxide synthesis in the conscious rat. Br J Pharmacol 1993; 110: 1213–21.PubMedCrossRef
105.
Patel BM, Chittock DR, Russell JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002; 96: 576–82.PubMedCrossRef
106.
Dünser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003; 107: 2313–9.PubMedCrossRef
107.
Klinzing S, Simon M, Reinhart K, et al. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003; 31: 2646–50.PubMedCrossRef
108.
Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2000; 102 (8 Suppl.): 11–3841.
109.
Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Resuscitation 2000; 46: 1–447.
110.
Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32: 858–73.PubMedCrossRef
111.
O’Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet 2002; 359: 1209–10.PubMedCrossRef
112.
van Haren FM, Rozendaal FW, van der Hoeven JG. The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest 2003; 124: 2256–60.PubMedCrossRef
113.
Obritsch MD, Bestul DJ, Jung R, et al. The role of vasopressin in vasodilatory septic shock. Pharmacotherapy 2004 Aug; 24(8): 1050–63.PubMedCrossRef
114.
Hall LG, Oyen LJ, Taner CB, et al. Fixed-dose vasopressin compared with titrated dopamine and norepinephrine as initial vasopressor therapy for septic shock. Pharmacotherapy 2004 Aug; 24(8): 1002–12.PubMedCrossRef
115.
Rodriguez-Nunez A, Fernandez-Sanmartin M, Martinon-Torres F, et al. Terlipressin for catecholamine-resistant septic shock in children. Intensive Care Med 2004 Mar; 30(3): 477–80.PubMedCrossRef
116.
Dünser MW, Mayr AJ, Stallinger A, et al. Cardiac performance during vasopressin infusion in postcardiotomy shock. Intensive Care Med 2002; 28: 746–51.PubMedCrossRef
117.
Rosenzweig EB, Stare TJ, Chen JM, et al. Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery. Circulation 1999; 100: II182–6.PubMedCrossRef
118.
Gold JA, Cullinane S, Chen J, et al. Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. Crit Care Med 2000; 28: 249–52.PubMedCrossRef
119.
Morales DL, Garrido MJ, Madigan JD, et al. A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. Ann Thorac Surg 2003; 75: 926–30.PubMedCrossRef
120.
Schummer W, Schummer C, Wippermann J, et al. Anaphylactic shock: is vasopressin the drug of choice? Anesthesiology 2004; 101: 1025–7.PubMedCrossRef
121.
Weisgerber K, Link A, Hammer B, et al. Vasopressin analogue injection as ultimate measure for counteracting severe catecholamine-refractory poisoning by several vasodilators taken with suicidal intent [in German]. Dtsch Med Wochenschr 2003; 128: 2189–92.PubMedCrossRef
122.
Yeh CC, Wu CT, Lu CH, et al. Early use of small-dose vasopressin for unstable hemodynamics in an acute brain injury patient refractory to catecholamine treatment: a case report. Anesth Analg 2003; 97: 577–9.PubMedCrossRef
123.
De Kock M, Laterre PF, Andruetto P, et al. Ornipressin (Por 8): an efficient alternative to counteract hypotension during combined general/epidural anesthesia. Anesth Analg 2000; 90: 1301–7.PubMedCrossRef
124.
Boccara G, Ouattara A, Godet G, et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin-angiotensin system inhibitors. Anesthesiology 2003; 98: 1338–44.PubMedCrossRef
125.
Veall GR, Peacock JE, Bax ND, et al. Review of the anaesthetic management of 21 patients undergoing laparotomy for carcinoid syndrome. Br J Anaesth 1994; 72: 335–41.PubMedCrossRef
126.
Augoustides JG, Abrams M, Berkowitz D, et al. Vasopressin for hemodynamic rescue in catecholamine-resistant vasoplegic shock after resection of massive pheochromocytoma. Anesthesiology 2004; 101: 1022–4.PubMedCrossRef
127.
Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive pharmacologic donor management results in more transplanted organs. Transplantation 2003; 75: 482–7.PubMedCrossRef
128.
Shelly MP, Greatorex R, Calne RY, et al. The physiological effects of vasopressin when used to control intra-abdominal bleeding. Intensive Care Med 1988; 14: 526–31.PubMedCrossRef
129.
Eyraud D, Brabant S, Nathalie D, et al. Treatment of intraoperative refractory hypotension with terlipressin in patients chronically treated with an antagonist of the renin-angiotensin system. Anesth Analg 1999; 88: 980–4.PubMed
130.
Overand PT, Teply JF. Vasopressin for the treatment of refractory hypotension after cardiopulmonary bypass. Anesth Analg 1998; 86: 1207–9.PubMed
131.
Mayr A, Knotzer H, Pajk W, et al. Risk factors associated with new onset tachyarrhythmias after cardiac surgery: a retrospective analysis. Acta Anaesthesiol Scand 2001; 45: 543–9.PubMedCrossRef
132.
Stump GL, Wallace AA, Gilberto DB, et al. Arrhythmogenic potential of positive inotropic agents. Basic Res Cardiol 2000; 95: 186–98.PubMedCrossRef
133.
Dünser MW, Mayr AJ, Tur A, et al. Ischemie skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med 2003; 31: 1394–8.PubMedCrossRef
134.
Takala J. Non-conventional vasopressors in septic shock: effects on hepatosplanchnic blood flow. Schweiz Med Wochenschr 2000; 130: 1937–41.PubMed
135.
Noguera I, Medina P, Segarra G, et al. Potentiation by vasopressin of adrenergic vasoconstriction in the rat isolated mesenteric artery. Br J Pharmacol 1997; 122: 431–8.PubMedCrossRef
136.
Hansen EF, Strandberg C, Hojgaard L, et al. Splanchnic haemodynamics after intravenous terlipressin in anaesthetised healthy pigs. J Hepatol 1999; 30: 503–10.PubMedCrossRef
137.
Dünser MW, Wenzel V, Mayr AJ, et al. Management of vasodilatory shock: defining the role of arginine vasopressin. Drags 2003; 63: 237–56.CrossRef
138.
Asfar P, Pierrot M, Veal N, et al. Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Crit Care Med 2003; 31: 215–20.PubMedCrossRef
139.
Asfar P, Hauser B, Ivanyi Z, et al. Low-dose terlipressin during long-term hyperdynamic porcine endotoxemia: effects on hepatosplanchnic perfusion, oxygen exchange, and metabolism. Crit Care Med 2005; 33: 373–80.PubMedCrossRef
140.
Guzman JA, Rosado AE, Kruse JA. Vasopressin vs norepinephrine in endotoxic shock: systemic, renal, and splanchnic hemodynamic and oxygen transport effects. J Appl Physiol 2003; 95: 803–9.PubMed
141.
Bernadich C, Bandi JC, Melin P, et al. Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension. Hepatology 1998; 27: 351–6.PubMedCrossRef
142.
Scharte M, Meyer J, Van Aken H, et al. Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep. Crit Care Med 2001; 29: 1756–60.PubMedCrossRef
143.
Westphal M, Stubbe H, Sielenkamper AW, et al. Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport. Intensive Care Med 2003; 29: 301–8.PubMed
144.
Voelckel WG, von Goedecke A, Fries D, et al. Treatment of hemorrhagic shock: new therapy options [in German]. Anaesthesist 2004; 53: 1151–67.PubMedCrossRef
145.
Roberts I, Evans P, Bunn F, et al. Is the normalisation of blood pressure in bleeding trauma patients harmful? Lancet 2001; 357: 385–7.PubMedCrossRef
146.
Bickell WH, Wall Jr MJ, Pepe PE, et al. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med 1994; 331: 1105–9.PubMedCrossRef
147.
Stadibauer KH, Wagner-Berger HG, Raedler C, et al. Vasopressin, but not fluid resuscitation, enhances survival in a liver trauma model with uncontrolled and otherwise lethal hemorrhagic shock in pigs. Anesthesiology 2003; 98: 699–704.CrossRef
148.
Voelckel WG, Raedler C, Wenzel V, et al. Arginine vasopressin, but not epinephrine, improves survival in uncontrolled hemorrhagic shock after liver trauma in pigs. Crit Care Med 2003; 31: 1160–5.PubMedCrossRef
149.
Krismer AC, Wenzel V, Voelckel WG, et al. Employing vasopressin as an adjunct vasopressor in uncontrolled traumatic hemorrhagic shock: three cases and a brief analysis of the literature. Anaesthesist 2005 Mar; 54(3): 220–4.PubMedCrossRef
Metadata
Title
Vasopressin During Cardiopulmonary Resuscitation and Different Shock States
A Review of the Literature
Authors
Dr Anette C. Krismer
Martin W. Dünser
Karl H. Lindner
Karl H. Stadlbauer
Viktoria D. Mayr
Hannes G. Lienhart
Richard H. Arntz
Volker Wenzel
Publication date
01-01-2006
Publisher
Springer International Publishing
Published in
American Journal of Cardiovascular Drugs / Issue 1/2006
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI
https://doi.org/10.2165/00129784-200606010-00005

Other articles of this Issue 1/2006

American Journal of Cardiovascular Drugs 1/2006 Go to the issue

Current Opinion

The Effects of Blood Pressure and Lipid Control on Kidney Allograft Outcome

Therapy in Practice

Septic Thrombophlebitis

Review Article

Pharmacological Prevention of Thromboembolism in Patients with Left Ventricular Dysfunction

Review Article

Diabetes Mellitus-Associated Atherosclerosis